About Tarsus Pharmaceuticals, Inc.
https://www.tarsusrx.comTarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
CEO
Bobak R. Azamian
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 135
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Guggenheim
Buy
HC Wainwright & Co.
Buy
Jefferies
Buy
Oppenheimer
Outperform
Barclays
Overweight
Goldman Sachs
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:3.78M
Value:$284.34M
BLACKROCK INC.
Shares:3.27M
Value:$245.75M
RTW INVESTMENTS, LP
Shares:3.18M
Value:$239.04M
Summary
Showing Top 3 of 235
About Tarsus Pharmaceuticals, Inc.
https://www.tarsusrx.comTarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $118.7M ▲ | $108.63M ▼ | $-12.59M ▲ | -10.6% ▲ | $-0.3 ▲ | $-12.13M ▲ |
| Q2-2025 | $102.66M ▲ | $118.61M ▲ | $-20.34M ▲ | -19.81% ▲ | $-0.48 ▲ | $-17.65M ▲ |
| Q1-2025 | $78.33M ▲ | $99.4M ▲ | $-25.12M ▼ | -32.07% ▲ | $-0.64 ▼ | $-22.45M ▼ |
| Q4-2024 | $66.41M ▲ | $85.9M ▲ | $-23.11M ▲ | -34.8% ▲ | $-0.6 ▲ | $-20.37M ▲ |
| Q3-2024 | $48.12M | $70.04M | $-23.42M | -48.67% | $-0.61 | $-20.68M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $401.84M ▲ | $534.56M ▲ | $199.48M ▲ | $335.08M ▲ |
| Q2-2025 | $381.14M ▼ | $494.99M ▼ | $162.38M ▲ | $332.61M ▼ |
| Q1-2025 | $407.92M ▲ | $500.75M ▲ | $158.29M ▲ | $342.46M ▲ |
| Q4-2024 | $291.38M ▼ | $376.99M ▲ | $152.46M ▲ | $224.53M ▼ |
| Q3-2024 | $316.95M | $376.3M | $138.82M | $237.48M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-12.59M ▲ | $18.26M ▲ | $-4.74M ▲ | $2.56M ▲ | $16.08M ▲ | $16.35M ▲ |
| Q2-2025 | $-20.34M ▲ | $-29.39M ▼ | $-51.7M ▼ | $1.95M ▼ | $-79.14M ▼ | $-30.39M ▼ |
| Q1-2025 | $-25.12M ▼ | $-20.65M ▲ | $-34.94M ▲ | $136.56M ▲ | $80.97M ▲ | $-21.24M ▲ |
| Q4-2024 | $-23.11M ▲ | $-22.18M ▼ | $-59.57M ▼ | $2.93M ▲ | $-78.83M ▼ | $-27.25M ▼ |
| Q3-2024 | $-23.42M | $-8.65M | $3.13M | $639K | $-4.88M | $-8.93M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Product | $110.00M ▲ | $80.00M ▼ | $100.00M ▲ | $120.00M ▲ |
CEO
Bobak R. Azamian
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 135
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Guggenheim
Buy
HC Wainwright & Co.
Buy
Jefferies
Buy
Oppenheimer
Outperform
Barclays
Overweight
Goldman Sachs
Neutral
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:3.78M
Value:$284.34M
BLACKROCK INC.
Shares:3.27M
Value:$245.75M
RTW INVESTMENTS, LP
Shares:3.18M
Value:$239.04M
Summary
Showing Top 3 of 235